Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD by Rabinovich, Roberto A. et al.
Circulating desmosine in patients with COPD. December, 2015 
- 0 - 
Circulating desmosine levels do not predict emphysema 
progression but are associated with cardiovascular risk and 
mortality in COPD 
 
Roberto A. Rabinovich1, Bruce E. Miller2, Karolina Wrobel3, Kareshma Ranjit1, Michelle 
C Williams4, Ellen Drost1, Lisa D. Edwards5, David A. Lomas6, Stephen I. Rennard7, 
Alvar Agustí8, Ruth Tal-Singer2, Jørgen Vestbo9, Emiel F.M. Wouters10, Michelle John11, 
Edwin J.R. van Beek12, John T Murchison13, Charlotte E Bolton11, William MacNee1 and 
Jeffrey T.J. Huang3; Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE) Investigators. 
 
1- Edinburgh Lung and the Environment Group Initiative (ELEGI), Centre for 
Inflammation and Research, Queens Medical Research Institute, Edinburgh; 
2- Respiratory Therapy Area Unit, GSK, King of Prussia, Pennsylvania, USA; 
3- Medical Research Institute, School of Medicine, University of Dundee, Scotland, UK; 
4- University/BHF Centre for Cardiovascular Science, Chancellor’s Building, SU305, 49 
Little France Crescent, Edinburgh EH16SUF, UK; 
5- PAREXEL International, Research Triangle Park, North Carolina, USA 
6- Faculty of Medical Sciences, University College London, London, UK; 
7- Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska, 
Omaha, NE, USA; Clinical Discovery Unit, AstraZeneca, Cambridge, UK; 
8- Servei de Pneumologia, Thorax Institute. Hospital Clinic, IDIBAPS, Universitat de 
Barcelona and CIBER Enfermedades Respiratorias (CIBERES), Spain; 
9- Centre for Respiratory Medicine and Allergy, Manchester Academic Health Science 
Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, 
UK; 
10- Department of Respiratory Medicine, Maastricht University Medical Centre, 
Maastricht, the Netherlands; 
11- Nottingham Respiratory Research Unit, School of Medicine, University of Nottingham, 
Nottingham, UK; 
12- Clinical Research Imaging Centre, Queens Medical Research Institute, Edinburgh. 
13- Department of Radiology, Royal Infirmary of Edinburgh, Scotland, UK. 
 
Correspondence: Roberto A. Rabinovich. ELEGI Colt Laboratory, Centre for Inflammation 
Research. The Queen`s Medical Research Institute, University of Edinburgh. 47 Little France 
Crescent. EDINBURGH, Scotland U.K. EH16 4TJ. 
Email: roberto.rabinovich@ed.ac.uk 
 
Authors Contributions: 
 
Conception and design: RR, WM, JH. 
Realisation, analysis and interpretation: RR, WM, JH, KR, MW. 
Drafting the manuscript for important intellectual contents: RR, WM, JH, BM, KW, KR, MW, 
ED, LE, DL, SR, AA, RTS, JV, EW, MJ, ChB, EVB, JM. 
 
Keywords:   COPD comorbidities and mortality, desmosine and elastin  
   degradation,  atherosclerosis, inflammation, biomarker. 
Body Text  
Word Count:  3480 
 
This article has an online Supplementary File.  
Circulating desmosine in patients with COPD. December, 2015 
- 1 - 
 
Take Home: 
 
 Elastin degradation is a hallmark of emphysema and may also have a role in the 
pathogenesis of atherosclerosis associated with COPD, however, the relationship 
between the levels of desmosine, a marker of elastin degradation, and emphysema 
or cardiovascular disease are not fully understood. This study shows that elevated 
plasma desmosine levels relate to cardiovascular comorbidities, atherosclerotic 
burden and aortic stiffness and predicts all-cause mortality in COPD, but do not 
relate to emphysema severity or progression. 
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ABSTRACT 
 
Elastin degradation is a key feature of emphysema and may have a role in the pathogenesis 
of atherosclerosis associated with COPD. Circulating desmosine is a specific biomarker of 
elastin degradation. We investigated the association between plasma desmosine (pDES) 
and emphysema severity/progression, coronary artery calcium score (CACS) and mortality. 
 
pDES was measured in 1,177 COPD patients and 110 healthy control subjects from two 
independent cohorts. Emphysema was assessed on chest CT scans. Aortic arterial stiffness 
was measured as the aortic–femoral pulse wave velocity. 
 
pDES was elevated in patients with cardiovascular disease (CVD) (p<0.005) and correlated 
with age (rho=0.39, p<0.0005), CACS (rho=0.19, p<0.0005) mMRC (rho=0.15, p<0.0005), 
6MWD (rho=-0.17, p<0.0005) and BODE index (rho=0.10, p<0.01), but not with emphysema, 
emphysema progression or FEV1 decline. pDES predicted all-cause mortality independently 
of several confounding factors (p<0.005). In an independent cohort of 186 patients with 
COPD and 110 control subjects, pDES levels were higher in COPD patients with CVD and 
correlated with arterial stiffness (p<0.05). 
 
In COPD, excess elastin degradation relates to cardiovascular comorbidities, 
atherosclerosis, arterial stiffness systemic inflammation and mortality, but not to emphysema 
or emphysema progression. pDES is a good biomarker of cardiovascular risk and mortality in 
COPD. 
 
Abstract word count 195 words  
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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is characterized by persistent 
progressive airflow limitation, and is associated with an enhanced inflammatory 
response in the lungs to the inhalation of noxious particles and gases [1]. COPD is 
also frequently complicated by the development of extra-pulmonary comorbidities 
that have important implications for morbidity and mortality [2], in particular 
cardiovascular disease (CVD ) [3, 4]. 
We have previously proposed that elastin degradation could potentially contribute to 
both the pulmonary and extra-pulmonary manifestations of COPD [5] and may 
represent a mechanistic link between emphysema and the increased risk of 
cardiovascular disease [6]. The destruction of elastin in alveolar walls by proteases 
as part of  chronic tobacco smoking-induced lung inflammation, is a central feature of 
the pathogenesis of emphysema [7]. Recent studies have shown that arterial 
stiffness, a biomarker of cardiovascular risk [8], is increased in COPD patients [6, 9, 
10]. Increased arterial stiffness may result from increased elastin degradation and a 
relative increase in collagen in arterial walls, as occurs with aging [11, 12] and 
atherosclerosis [13]. Indeed we have shown that increased arterial stiffness in COPD 
is associated with increased elastin degradation in the skin [14] and with emphysema 
in COPD patients [15]. 
Thus, elastin degradation could potentially contribute to both the pulmonary and 
extra-pulmonary manifestations of COPD [5] and may represent a mechanistic link 
between COPD and the increased risk of cardiovascular disease in this condition [6]. 
Desmosine, and its isomer iso-desmosine, result from the condensation of four lysine 
residues in and between elastin proteins after oxidation by lysyl-oxidase and are 
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released when elastin is degraded. These represent ideal biomarkers to monitor 
elastin degradation since these special cross-links exist only in mature elastin [16]. 
The potential of desmosine, usually measured in urine, as a biomarker for pulmonary 
emphysema has been extensively studied in the last 40 years. However, inconclusive 
results have hindered its potential utility [16]. With improvements in analytical 
methods [17-19], we recently demonstrated that plasma total desmosine is elevated 
in 30-40% of COPD patients [18], results that were confirmed in a larger study [20]. 
However, the potential of plasma desmosine (pDES) as a biomarker of the severity 
or progression of emphysema and its role as a marker of cardiovascular 
comorbidities in COPD remains unclear. 
 The aim of this study was to explore the relationship of pDES with emphysema, 
emphysema progression, cardiovascular comorbidities, coronary artery calcium 
score (CACS), as a surrogate of coronary atherosclerosis, and mortality in a cohort of 
patients with COPD from the Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE) study. A second independent cohort was used to 
extend the findings in the ECLIPSE cohort. 
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METHODS 
 
Study Population and Ethics 
Nine hundred and ninety one stable patients with COPD from the ECLIPSE study 
[21], and 186 patients with COPD and 110 age, gender and smoking matched 
controls from a second independent cohort (The Association of Lung Function and 
Cardiovascular Risk – Nottingham) [22], were studied. 
All subjects were > 40 years old of European descent, and had a smoking history of 
≥10 pack years. Patients with COPD in both cohorts were current or ex-smokers (≥10 
pack years), with baseline post-bronchodilator FEV1<80% of predicted and 
FEV1/FVC<0.7 and were studied when clinically stable.  
Ethics committees of all participating institutions approved the study and written 
informed consent was obtained from all subjects. 
 
MEASUREMENTS 
 
Circulating inflammatory biomarkers 
In blood samples from the ECLIPSE cohort, inflammatory markers were measured in 
serum or plasma as previously described [23, 24]. 
 
Plasma desmosine (pDES) measurements 
Total pDES concentration was measured using a modified assay of a validated 
isotope dilution LC-MS/MS method [17] at year 1 and 2 in the ECLIPSE cohort and at 
baseline in the Nottingham cohort. 
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Computed tomography 
In the ECLIPSE study, subjects underwent a low-dose chest CT scan (GE 
Healthcare or Siemens Healthcare) at baseline, year 1 and 3. All CT scans were 
analysed at a central laboratory using Pulmonary Workstation 2.0 software (VIDA 
Diagnostics, Coralville, IA. USA) [25]. 
Emphysema was measured as the percentage of low attenuation areas < -950 
Hounsfield units in the whole lung (%LAA) or the 15th percentile of the frequency 
histogram of lung density values when the progression of emphysema was 
assessed, as previously described [26]. Emphysema was considered to be present if 
%LAA was greater than 10 % [25]. The %LAA was also assessed as a continuous 
variable. 
 
Coronary artery calcium score (CACS) 
CACS was assessed on CT lung images in the ECLIPSE cohort with a low spatial 
frequency algorithm as previously described [27] with images analysed using the 
Agatston scoring method [28]. 
 
Arterial stiffness  
Arterial stiffness was measured in the Nottingham cohort as the carotid - femoral 
pulse wave velocity (aortic pulse wave velocity, PWV) using Vicorder (Skidmore 
Medical, UK) in triplicate and the average recorded [29]. 
 
Statistical analysis 
Data are expressed as meanSD. pDES levels between paired samples was 
assessed using Wilcoxon test. Comparisons between groups were conducted using 
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analysis of variance (ANOVA) with Student-Newman-Keuls as a post-hoc test or the 
Kruskall Wallis equivalent with Dunn’s test as a post-hoc test for non-normally 
distributed variables. Analysis of covariance (ANCOVA) was used to control for 
potential confounders. Chi square tests were used to compare frequencies. 
Correlations were calculated as Pearson’s correlation coefficient or Spearman’s 
correlation coefficient for non-normally distributed variables. Logistic regression was 
conducted to describe the effect of several covariates on death as an event (as the 
dependent variable). 
A Cox proportional hazards models was constructed to compare mortality between 
subject groups. Analyses were conducted using the SAS Version 9.3 (SAS Institute 
Inc, Cary, NC, USA). Benjamini-Hochberg False Discovery Rate (FDR) method was 
used to adjust the multiple hypothesis tests. 
(See online data supplement for more details on the methods). 
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RESULTS 
 
Investigation of elastin degradation in the ECLIPSE cohort 
 
Of the 2746 subjects enrolled in ECLIPSE, one thousand COPD patients were 
included in the study. This cohort of patients was selected to cover for the whole 
spectrum of severity in lung function, lung function decline and emphysema 
progression (between baseline and year 3). A total of 991 blood samples from year 1 
were available for analysis. From these, 813 patients with COPD had CT scans 
available for analysis after the exclusion of scans with poor image quality [27]. The 
demographic details of the study population are shown in Table 1 and a comparison 
between the patients in the ECLIPSE cohort not included in the study and the 
present cohort is shown in the online supplement Table S1. The two populations 
were similar in age, gender, body composition, and smoking history. There were 
statistically significant differences in lung function and 6MWD, however, these 
differences were very small and considered to be clinically irrelevant. 
 
pDES and patient characteristics 
pDES levels in the ECLIPSE cohort correlated positively and significantly (univariate 
analysis) with age (rho=0.39, p<0.0005), mMRC (rho=0.15, p<0.0005), BODE index  
(rho=0.10, p<0.01), hospitalisations  (rho=0.08, p<0.05), pack/years (rho=0.07, 
p<0.05) and the CACS score (rho=0.19, p<0.0005). pDES correlated negatively with 
FVC (rho=-0.09, p<0.05), 6MWD (rho=-0.17, p<0.0005) and SpO2 (rho=-0.1, p<0.05). 
Significant positive correlations were found between pDES levels and inflammatory 
biomarkers: fibrinogen (rho=0.12, p<0.001), IL-6 (rho=0.15, p<0.0005), IL-8 
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(rho=0.11, p<0.005), CCL-18 (rho=0.13, p<0.0005) and SP-D (rho=0.10, p<0.01). No 
difference in pDES levels was observed between genders. Most of these correlations 
(except age) are considered weak albeit significant correlations (as a result of large 
sample size). 
Subjects were divided into quartiles of pDES levels. The highest pDES quartile had 
significantly higher values for age, mMRC dyspnoea score, number of 
hospitalisations recorded in the three years of the study, fibrinogen, IL-6, CCL-18, 
SP-D and lower values of 6MWD (Table 2S). 
 
Changes in pDES in stable COPD over 1 year and characteristics of patient 
with persistent elastin degradation  
From the 991 patients assessed at year one, 981 samples were available for pDES 
assessment one year later. The levels at the two visits were significantly correlated 
(r=0.37; p<0.0001). There were no significant differences between pDES levels 
measured at year 1 and 2 (p=0.75), and mean differences (bias) between both 
assessments was 0.0019 ng/mL showing a good stability of pDES in repeated 
assessments (Figure 1S, online supplement). We have also shown in a previous 
report a small short term intra-subject variability of pDES over two weeks [18]. This 
allowed us to use a nominal cut-off pDES of 0.35 ng/mL calculated from the mean + 
2.575 x standard deviation (to achieve the 99% confidence level) derived from 
healthy volunteers in a previous study [18]. We found that ≈approximately 50% of 
patients in the ECLIPSE cohort had abnormal elastin degradation at year 1, which 
(65%) continued to have high elastin degradation activity one year later. In the other 
50% of patients that had low initial pDES levels, most (63%) continued to have low 
pDES levels one year later. To investigate potential relationships between persistent 
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elastin degradation and patient characteristics, patients were divided into four groups 
according to the nominal cut-off for pDES: pDESLL (n=312): with normal levels of 
pDES at both visits (persistently low), pDESLH (n=180): normal levels at year 1 but 
high levels at year 2, pDESHL (n=173): high levels at year 1 and normal levels at year 
2; and, pDESHH (n=316): with high pDES levels at both time points (persistently high). 
pDESHH patients were older, had lower FEV1, SpO2 and 6MWD and higher mMRC, 
number of years smoked, BODE index, number of hospitalisations recorded in the 
first three years of the study, fibrinogen, IL-6, CCL-18 and circulating neutrophils in 
comparison to pDESLL (Table 2).  
 
The relationship between pDES and emphysema and FEV1 severity and 
progression  
No differences in pDES were seen between patients with and without emphysema on 
CT scan (p=0.68) and no significant correlations were found between pDES and 
emphysema (%LAA)) (rho=0.07, p=ns), emphysema progression (change in PD15) 
(rho=0.02, p=ns), FEV1 (rho=-0.05, p=ns), or FEV1 decline (rho=-0.01, p=ns), There 
were no differences in %LAA between the different pDES quartiles (p=0.27) or 
between pDESLL and pDESHH patients (Kruskal Wallis p=0.01, Dunn post hoc test: 
significance only between pDESLN and pDESNL). 
 
pDES and cardiovascular comorbidity 
 A self-reported history of cardiovascular disease (CVD) was present in 25% of 
patients (Table 1). pDES was higher in patients with a history of CVD compared to 
those without CVD (p<0.005) and specifically in patients with hypertension 
(p<0.0005), heart attack (p<0.05) and heart failure (p<0.05) (Figure 2S, online 
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supplement). 
We further investigated the relationship between aortic calcification, a surrogate for 
atherosclerotic burden, and elastin degradation. CACS was significantly higher in the 
highest pDES quartile compared with all other quartiles at both year 1 and 2 
(p<0.0005, Figure 3S). After correcting for %LAA, age, gender, cumulative smoking 
history (pack/year history), years smoked and inflammation, the significance remains 
for year 2 results but year 1, suggesting the correlation is confounded with these 
variables. When grouping based on pDES levels at both visits. pDESHH patients had 
a higher Agatston score in comparison with pDESLL, pDESLH and pDESHL patients 
(p<0.0005) (Figure 1A) and remained significant after correcting for the mentioned 
confounders. 
Patients were divided into commonly defined CACS groups [27], low (<100 Agatston 
units (AU)), intermediate (101–400 AU), high (401– 1000 AU) or very high (>1000 
AU) CACS. Patients with very high Agatston score at baseline were more likely to 
have high pDES levels in the subsequent two years (pDESHH) (Figure 1B), showing 
that persistently high pDES levels associate with very high Agatston score. 
 
pDES and mortality  
pDES levels were higher in patients who died during the three years follow-up period 
(p<0.001) than in those who survived. Patients who died during the three years 
follow-up period had also higher values for age, fibrinogen, IL-6 and CCL18. 
In a logistic regression with death as the dependent variable and pDES, age, gender, 
smoking history, mMRC, hospitalisations, inflammation, CACS and cardiovascular 
comorbidities as independent variables, only pDES was significantly associated with 
mortality (p<0.005). For a 0.1 ng/mL of change in pDES the odds ratio is 1.31 
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(95%CI: 1.12,1.54). Given the other variables in the model are held constant, the 
odds of death increased by 31 % for each 0.1 ng/mL increase in pDES. A Cox 
proportional hazards model for patients with COPD and pDES quartiles adjusted for 
age, gender, smoking history, mMRC, hospitalisations, inflammation, CACS and 
cardiovascular comorbidities showed that patients in the highest pDES quartile had a 
significantly lower probability of survival (p<0.05) (Figure 2). 
 
Patients with persistently high pDES (pDESHH) had a higher risk of dying during the 3 
years follow-up than the other pDES groups, however, this difference is likely to be 
driven by age and smoking history as the significance disappeared when adjusted for 
age, gender and smoking history. 
 
The relationship between pDES and arterial stiffness in the Nottingham cohort 
To further evaluate the relationship between pDES and cardiovascular comorbidities 
and risk in COPD and to eliminate the potential influence of kidney function on pDES 
levels, an independent cohort [22] of 186 COPD patients and 110 age-gender- and 
smoking -matched controls (Table 1) was studied. COPD patients in this cohort had 
a similar gender distribution, BMI, pack/years history and SpO2 but were slightly 
older, had a slightly higher FEV1 and worse mMRC compared with the ECLIPSE 
cohort. pDES levels were not significantly different between the two COPD cohorts 
and so was the proportion of patients expressing abnormal levels of pDES (54% 
[Nottingham] vs 50% [ECLIPSE]). 
 
pDES and PWV 
Patients with COPD in the Nottingham cohort had significantly higher pDES 
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(0.380.16 ng/mL) than controls (0.300.15 ng/mL; p<0.0001) and higher PWV 
(10.32.1 m/sec) than controls (9.61.9 m/sec; p<0.005).  
In COPD patients, pDES correlated positively with age (r=0.38, p<0.0001) and PWV 
(r=0.15, p<0.05) and negatively with FEV1 (r=-0.19, p<0.01).  pDES was also higher 
in patients with COPD and a history of ischemic heart disease (IHD)(0.430.18 
ng/mL) compared to those without  IHD (0.370.15 ng/mL; p=0.05). 
 
pDES levels and renal function 
There was no significant correlation between pDES and creatinine levels (rho=0.09, 
p=ns) or estimated glomerular filtration rate (eGFR) (rho=-0.14, p=ns) nor any 
differences in creatinine levels (p=0.59) eGFR (p=0.16) between the different pDES 
quartiles or between patients with normal and abnormal levels of pDES (creatinine 
levels p=0.25, eGFR p=0.18) or between COPD patients and controls (creatinine 
levels p=0.89, eGFR p=0.65). 
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DISCUSSION 
In the largest study of its kind to date, we have shown that elevated pDES levels 
relate to cardiovascular comorbidities, aortic stiffness, and mortality in patients with 
COPD, but not to emphysema, emphysema progression, as assessed by CT scan, or 
FEV1 decline. The association to coronary artery disease was particularly significant 
in patients with persistently elevated levels of pDES. We also confirmed that patients 
with COPD had higher pDES compared with age- and gender-matched controls. 
These observations suggest that pDES is predominantly a reflection of elastin 
degradation in vascular tissue, potentially caused by aberrant inflammation in 
vascular tissues, contributing to worse cardiovascular outcomes and mortality. This 
notion is supported by results in a second independent cohort where pDES was 
related to cardiovascular comorbidities and aortic PWV as a measure of arterial 
stiffness, suggesting that increased arterial stiffness may also result from systemic 
elastin degradation in the arterial walls [14].  
In contrast, the lack of association between pDES levels and emphysema 
progression or lung function decline, as assessed by CT scan, suggests that pDES is 
not a good biomarker of lung elastin degradation.  
 
Our study contrasts with previous studies that have shown associations between 
lung function [20] or measurements of emphysema [18, 20] and desmosine levels. 
These differences may be explained by differences in the patient populations studied 
and differences in the measurements of emphysema (or its surrogate) between 
studies. We have used measurement of emphysema on CT scans as a direct 
assessment of emphysema rather than surrogates such as the diffusing capacity for 
carbon monoxide. Moreover, we selected our population based on emphysema, lung 
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function, emphysema progression and lung function decline. This has enabled us to 
be in the best position to assess the relationship between these parameters and 
pDES.  
 
We suspect that the relative size of cardiovascular tissues compared to the lung may 
be one explanation for these results. The average adult lung weighs about 1.3 kg of 
which 28% is elastin protein [30], compared to 4.9 kg of the cardiovascular system 
(based on 7% of body weight of a 70 kg adult), of which up to 50% of its dry weight 
consists of elastin [31]. Therefore, the contribution from the cardiovascular system to 
circulating desmosine may be greater than the lungs. Sputum desmosine, which is 
increased in COPD patients [32], may be a more sensitive marker of lung elastin 
degradation. The lack of relationship between pDES and emphysema, as assessed 
by CT scan, may also relate to diminished lung elastin content in patients with 
emphysema who have less lung tissue. In addition, processes that affect lung density 
other than emphysema could contribute to masking a relationship with desmosine. 
Finally, another possible source of pDES could be from elastin degradation in the 
skin since we have already shown evidence of increased elastin degradation in the 
skin of patients with COPD compared to matched controls [14].  
As the products of elastin degradation - elastokines - can actively participate in the 
progression of atherosclerosis by accelerating LDL oxidation and calcification of the 
vascular wall [33], it is also possible that the association observed was indirect or a 
combination of direct and indirect effects.  
Vascular elastin degradation has previously been shown to occur in several 
conditions such as atherosclerosis [33], aortic aneurysms [34] , hypertension [35] and 
chronic kidney disease [36]. However, evidence of the role of pDES as a prognostic 
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biomarker is scarce and inconsistent. Noticeably, increased elastin degradation as 
assessed by elastin–derived peptides was associated with increased arterial stiffness 
and with all-cause mortality in chronic kidney disease [36]. In contrast, the EVA study 
[37] showed that a decrease in serum elastin peptide levels was associated with risk 
factors for atherosclerosis-related diseases. Our results in a cohort of COPD patients 
are consistent with the former. While the discrepancy between these studies is 
unexplained, we suspect that differences in analytical methods, and the study 
population are the likely causes. MMP2 and cathepsin-S were implicated as key 
enzymes for the vascular elastin degradation in chronic kidney [36] and lungs [38] 
diseases, but have never been investigated in the vascular bed in COPD patients. 
Interestingly, we have shown increased MMP2 and MMP9 gene expression 
associated with increased elastin degradation in the skin of patients with COPD [14].  
Our results suggest that elevated elastin degradation is persistent in a subgroup of 
COPD patients (e.g. ~30% in the ECLIPSE cohort). This sub-group appears to be 
older with worse mMRC, BODE index, 6MWD, SpO2 and CACS, as well as exhibiting 
high levels of inflammatory biomarkers. Since pDES levels did not correlate with 
FEV1 decline in COPD and excess elastin degradation can occur at an early state of 
the disease, timely identification of this subgroup of patients may offer an attractive 
strategy for therapeutic and/or lifestyle intervention to improve clinical outcomes.  
Our results indicate that pDES is a predictor of all-cause mortality in COPD patients. 
Several other biochemical biomarkers are also able to predict mortality in COPD 
patients including fibronectin to C-reactive protein ratio [39] and other inflammatory 
biomarkers [40]. However, in a logistic regression analysis only pDES was 
significantly related to death after correcting for several variables including 
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inflammatory markers. pDES may  therefore be a good  biomarker to identify COPD 
patients at-risk of death and cardiovascular comorbidity.  
As kidney is the major route for desmosine excretion [41], pDES levels could 
potentially be affected by renal function. We found no difference in renal function 
between COPD patients and controls in the Nottingham cohort, nor any significant 
relationship between renal function and pDES. Thus we believe that our observations 
are not confounded by differences in renal function. 
 
Study limitations 
Our study has some limitations. The two cohorts included in this study do not have 
the same measurements nor did the second cohort have repeated sampling. 
Therefore we were not able to validate either the lack of relationship between pDES 
and emphysema or the relationship between prospective changes in pDES and 
outcomes, nor the positive correlation with CACS. However, this was not the main 
reason for the inclusion of this second cohort, which was to determine if there was a 
relationship between pDES and arterial stiffness. It also allowed us to confirm the 
finding of the relationship between pDES and CVD, and to exclude potential effect of 
renal function. The confirmation of an association between pDES and cardiovascular 
risk assessed in a totally independent cohort and with a different marker of 
cardiovascular risk is, therefore, a strength of this study. Unfortunately, due to the low 
prevalence of cardiovascular disease in the control group in the Nottingham cohort, it 
was not possible to explore the relationship between pDES and CVD in the healthy 
subjects.  
 
Conclusions 
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Our study shows that pDES in patients with COPD is a useful marker of 
cardiovascular risk and all-cause mortality and may reflect a mechanistic link 
between COPD and increased cardiovascular risk. 
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TABLE 1. CHARACTERISTICS OF THE STUDY GROUP 
 
ECLIPSE  
COPD 
 
NOTTINGHAM  
COPD 
 
NOTTINGHAM 
Controls 
COPD ECLIPSE 
Vs COPD 
NOTTINGHAM 
p-value 
COPD Vs 
Control 
NOTTINGHAM 
p-value 
n 991 186 110   
Men 633 (64%) 116 (62%) 67 (61%) NS  
Hypertension (%) 41 31 27   
Angina (%) 11 18 7   
Heart Attack (%) 10     
Heart Failure (%) 6     
Stroke (%) 4     
Age (Years) 63  7.2 68  7.8 65  9.8 <0.0005 NS 
BMI (kg.m
-2
) 26.8  5.8 27.2  5.6 27.7  4.6 NS NS 
Pack/Year 47.4  26.0 44.2  25.7 29.4  18.6 NS <0.0001 
mMRC 2.6  1.0 2.9  1.1 1.4  0.6 <0.01 <0.005 
FEV1 (L) 1.4  0.5 1.5  0.6 2.8  0.7 <0.05 <0.0001 
FEV1 (% pred) 50.5  15.2 57.9  18.5 99.9  13.8 <0.0005 <0.0001 
FVC (L) 3.1  0.9 3.1  0.9 3.8  1.0 NS <0.0001 
FVC (% pred) 89.2  19.7 93.8  19.9 109.1  17.3 <0.0005 <0.0001 
FEV1/FVC 0.46  0.1 0.49  0.13 0.74  0.07 <0.005 <0.0001 
SpO2 (%) 94.7  2.8 94.6  2.4 95.5  8.4 NS <0.0001 
6MWD (m) 384  118.9     
6MWD (%pred) 59.5  18.0     
BODE 2.9  2.0     
        
 
Definition of abbreviations: COPD = patients with Chronic Obstructive Pulmonary Disease; BMI = Body mass index; Pack/Year: cumulative history of smoking; 
mMRC = modified medical research council dyspnoea score; FEV1 = forced expiratory volume in the first second; FVC = forced vital capacity; SpO2 = oxygen 
saturation; 6MWD = six minute walking distance; BODE= BODE index. Benjamini Hochberg correction was applied to prevent α-error accumulation.  
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TABLE 2S. Desmosine Groups 
Definition of abbreviations: pDESLL: pDES normal in both assessments (initial and 1 year follow-up); pDESHH: pDES high values in both assessments. 
mMRC = modified medical research council dyspnoea score; Hospitalisations = number of hospitalisations recorded in the first three years of the study; 
6MWD = six minute walking distance; BODE= BODE index; %LAA: per cent low attenuation areas ;-950 Hounsfield units; IL-6: Interleukin six; IL-8: 
Interleukin eight; CCL-18: Chemokine (C-C motif) ligand eighteen; CACS: coronary artery calcification score. Comparisons among groups were done 
using Wilcoxon test and Dunn test as a post-hoc test. Benjamini Hochberg correction was applied to prevent α-error accumulation.  (* statistical 
difference between pDESLL and pDESHH). 
 
  
 pDESLL pDESLH pDESHL pDESHH 
p-
value 
n (%) 312 (32%) 180 (18%) 173 (18%) 316 (32%) 
NS Current/former 
smokers 
41/59 36/64 36/64 34/66 
 Age (Years) 59.7  7.4 62.4  6.7 63.0  6.6 66.7  5.7* <0.0005 
FEV1 (L) 1.4  0.5 1.3  0.5 1.3  0.4 1.2  0.4* <0.05 
SpO2 (%) 95.2  2.7 94.7  3.1 94.5  2.8 94.5  2.6* <0.005 
mMRC 1.4  1.0 1.6  1.0 1.6  1.0 1.8  1.1* <0.0005 
Pack/Year 44.0  24.3 49.6  29.8 48.7  20.9 48.1  27.9 <0.01 
Years Smoked 37.7  8.8 39  8.8 39.3  10.1 41.0  10.7* <0.0005 
Hospitalisations 0.55  1.5 0.63  1.3 0.71  1.6 0.79  1.6* <0.01 
6MWD (m) 413.8  120.6 382.5  121.0 386.8  110.5 354.7  115.4* <0.0005 
BODE index 2.5  2.0 3.0  1.9 2.8  2.0 3.2  2.0* <0.0005 
%LAA 14.7  10.9 17.7  11.6 17.0  11.5 17.2  11.7 <0.05 
Fibrinogen (mg/dL) 437.7  94.4 463.8  97.9 447.4  93.0 474.7  104.9* <0.0005 
IL-6 (pg/mL) 2.8  11.1 4.2  12.6 4.4  15.5 6.7  41.6* <0.0005 
IL-8 (pg/mL) 14.2  37.8 14.6  33.3 12.4  18.0 14.1  36.5* <0.005 
CCL-18 (pg/mL) 104.7  38.8 111.1  41.0 109.9  44.6 121.1  47.8* <0.0005 
Lymphocytes 2.0  0.7 2.1  0.6 2.1  0.7 1.9  0.6* <0.0005 
Lymphocytes (%) 26.9  7.6 26.5  7.5 27.5  8.2 24.4  7.4* <0.0005 
Neutrophils 5.0  1.7 5.3  2.0 4.9  1.7 5.3  1.9 <0.05 
Neutrophils (%) 63.7  8.4 64.0  8.3 63.0  8.6 66.0  8.4* <0.005 
SP-D (pg/mL) 131.7  65.5 139.1  95.3 139.6  69.4 144.7  80.7 NS 
CACS 267.9  500.5 470.9  831.3 373.6  577.1 651.7  967.8 <0.0001 
Cardiovascular hist. 58 (25.1%) 40 (17.3%) 37 (16.0%) 96 (41.6%) <0.005 
Hypertension (%) 92 (24.2%) 77 (20.3%) 59 (15.5%) 152 (40.0%) <0.0001 
Angina (%) 32 (31.1%) 13 (12.6%) 18 (17.5%) 40 (38.8%) NS 
Heart Attack (%) 21 (22.8%) 14 (15.2%) 16 (17.4%) 41 44.6(%) <0.05 
Heart Failure (%) 11 (21.6%) 7 (13.7%) 13 (25.5%) 20 (39.2%) NS 
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FIGURE LEGENDS 
 
 
 
Figure 1: Relationship between pDES and CACS. 
Panel A shows levels of CACS in the four different pDES groups after 
correcting for %LAA, age, cumulative smoking history (Pack/years) and years 
smoked. (*p<0.0005). 
 
Panel B shows patient’s distribution in the different CACS categories (low, 
intermediate, high and very high) according to their pDES at year 1 and year 2. 
pDESLL (normal pDES levels at both visits,  ), pDESLH (normal levels at year 
1that increase 1 year later, ), pDESHL (high levels at year 1  but returning to 
normal levels one year later, ) or pDESHH (high levels of pDES at both visits, 
). (Chi2 p<0.0001). 
 
 
 
Figure 2: Survival probability in relationship to pDES. 
Cox proportional hazard model for patients with COPD and pDES quartiles 
adjusted for age, gender, smoking history, hospitalisations, inflammation and 
CACS. (*p<0.05). A similar result was observed in an unadjusted Cox model 
(data not shown). 
 
 
 
 
